Immunomic Therapeutics, Inc. (ITI), a privately-held, Maryland-based biotechnology company, today announced the issuance of a new United States Patent which extends ITI’s intellectual property portfolio covering their proprietary vectors, including ITI’s out-licensed investigational DNA vaccines. Specifically, U.S. Patent No. 9,499,589 (‘589 Patent) issued on November 22, 2016, entitled “Chimeric Vaccines.”